PAK5 (p21 (RAC1) activated kinase 5)

2006-10-01  

Identity

HGNC
LOCATION
20p12.2
LOCUSID
ALIAS
PAK7

Other Information

Locus ID:

NCBI: 57144
MIM: 608038
HGNC: 15916
Ensembl: ENSG00000101349

Variants:

dbSNP: 57144
ClinVar: 57144
TCGA: ENSG00000101349
COSMIC: PAK5

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000101349ENST00000353224Q9P286
ENSG00000101349ENST00000378423Q9P286
ENSG00000101349ENST00000378429Q9P286

Expression (GTEx)

0
5
10
15
20
25
30
35
40

Pathways

PathwaySourceExternal ID
ErbB signaling pathwayKEGGko04012
Axon guidanceKEGGko04360
Focal adhesionKEGGko04510
T cell receptor signaling pathwayKEGGko04660
Regulation of actin cytoskeletonKEGGko04810
Renal cell carcinomaKEGGko05211
ErbB signaling pathwayKEGGhsa04012
Axon guidanceKEGGhsa04360
Focal adhesionKEGGhsa04510
T cell receptor signaling pathwayKEGGhsa04660
Regulation of actin cytoskeletonKEGGhsa04810
Renal cell carcinomaKEGGhsa05211
Ras signaling pathwayKEGGhsa04014
Developmental BiologyREACTOMER-HSA-1266738
Axon guidanceREACTOMER-HSA-422475
Signaling by Robo receptorREACTOMER-HSA-376176
Activation of RacREACTOMER-HSA-428540

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
374378272023PAK5 potentiates slug transactivation of N-cadherin to facilitate metastasis of renal cell carcinoma.0
374378272023PAK5 potentiates slug transactivation of N-cadherin to facilitate metastasis of renal cell carcinoma.0
352421382022The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.5
369052682022PAK5 is a potential target in myelodysplastic syndrome through interacting with LMO2 and GATA1.0
352421382022The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.5
369052682022PAK5 is a potential target in myelodysplastic syndrome through interacting with LMO2 and GATA1.0
335421802021P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer.4
341436942021MiR-145-5p modulates lipid metabolism and M2 macrophage polarization by targeting PAK7 and regulating β-catenin signaling in hyperlipidemia.4
341650022021Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma.5
345867422021PAK5-stabilized Smuc confers renal cell carcinoma metastasis.2
349368742021PAK5 promotes RNA helicase DDX5 sumoylation and miRNA-10b processing in a kinase-dependent manner in breast cancer.9
335421802021P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer.4
341436942021MiR-145-5p modulates lipid metabolism and M2 macrophage polarization by targeting PAK7 and regulating β-catenin signaling in hyperlipidemia.4
341650022021Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma.5
345867422021PAK5-stabilized Smuc confers renal cell carcinoma metastasis.2

Citation

Dessen P

PAK5 (p21 (RAC1) activated kinase 5)

Atlas Genet Cytogenet Oncol Haematol. 2006-10-01

Online version: http://atlasgeneticsoncology.org/gene/43394/pak5-(p21-(rac1)-activated-kinase-5)